Loading cancer entity…
Loading cancer entity…
Clinical trials
3,221 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (571)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04129515 | NovoTTF-200A + Pembrolizumab In Melanoma Brain Metastasis | withdrawn | Phase 1 / Phase 2 | 0 | Brown UniversityOTHER | 1 | Jan 2, 2026 | clinicaltrials |
| NCT06626256 | STIL101 for Injection for the Treatment of Locally Advanced, Metastatic or Unresectable Pancreatic Cancer, Colorectal Cancer, Renal Cell Cancer, Cervical Cancer and Melanoma | withdrawn | Phase 1 | 0 | City of Hope Medical CenterOTHER | 0 | Dec 24, 2025 | clinicaltrials |
| NCT05717140 | Aerosolized Sargramostim Added to Immunotherapy for the Treatment of Patients With Metastatic Melanoma to the Lung | withdrawn | Phase 1 | 0 | Mayo ClinicOTHER | 1 | Aug 7, 2025 | clinicaltrials |
| NCT06190249 | Efficacy & Safety for LN144 With Pembrolizumab With High Risk Stage IIIb-dResectable Melanoma | withdrawn | Phase 1 | 0 | James Isaacs, MDOTHER | 0 | Jun 5, 2025 | clinicaltrials |
| NCT02145910 | Vemurafenib Combined With Whole Brain Radiation Therapy or Radiosurgery in Patients With BRAF Mutation-Positive Melanoma and Brain Metastases | withdrawn | Phase 1 | 0 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson UniversityOTHER | 0 | May 2, 2025 | clinicaltrials |
| NCT03167177 | QUILT-3.046: NANT Melanoma Vaccine: Combination Immunotherapy in Subjects With Melanoma Who Have Progressed On or After Chemotherapy and PD-1/PD-L1 Therapy | withdrawn | Phase 1 / Phase 2 | 0 | ImmunityBio, Inc.INDUSTRY | 0 | Feb 21, 2025 | clinicaltrials |
| NCT05653661 | Nab-Paclitaxel/STI-3031 Complex (AP160-Complex) for the Treatment of Advanced or Metastatic Solid Tumors | withdrawn | Phase 1 | 0 | Mayo ClinicOTHER | 1 | Jan 7, 2025 | clinicaltrials |
| NCT02535078 | Phase 1b/2 Study of the Combination of IMCgp100 With Durvalumab and/or Tremelimumab in Advanced Cutaneous Melanoma | withdrawn | Phase 1 / Phase 2 | 0 | Immunocore LtdINDUSTRY | 1 | Jul 24, 2024 | clinicaltrials |
| NCT02143050 | Study of Dabrafenib, Trametinib and Metformin for Melanoma Patients | withdrawn | Phase 1 / Phase 2 | 0 | University of LouisvilleOTHER | 1 | Nov 18, 2023 | clinicaltrials |
| NCT06090318 | Milademetan in Combination With Atezolizumab in Patients With Advanced Solid Tumors With CDKN2A Loss | withdrawn | Phase 1 / Phase 2 | 0 | Rain Oncology IncINDUSTRY | 0 | Oct 19, 2023 | clinicaltrials |
| NCT05677373 | Testing the Safety and Effectiveness of Combining Two Drugs, PLX2853 and Trametinib in the Treatment of Advanced Uveal Melanoma | withdrawn | Phase 1 / Phase 2 | 0 | Alliance for Clinical Trials in OncologyOTHER | 0 | Aug 18, 2023 | clinicaltrials |
| NCT04759846 | Hepatic Impairment Study of Encorafenib in Combination With Binimetinib in BRAF Melanoma | withdrawn | Phase 1 | 0 | Pierre Fabre MedicamentINDUSTRY | 3 | Feb 21, 2023 | clinicaltrials |
| NCT05572463 | A Platform Study of Novel Immunotherapy Products in Participants With Previously Treated Unresectable or Metastatic Cutaneous Melanoma | withdrawn | Phase 1 / Phase 2 | 0 | Innovent Biologics (Suzhou) Co. Ltd.INDUSTRY | 7 | Nov 18, 2022 | clinicaltrials |
| NCT04648826 | Aerosolized Azacytidine as Epigenetic Priming for Bintrafusp Alfa-Mediated Immune Checkpoint Blockade in Patients With Unresectable Pulmonary Metastases From Sarcomas, Germ Cell Tumors, or Epithelial Malignancies | withdrawn | Phase 1 / Phase 2 | 0 | National Cancer Institute (NCI)NIH | 1 | Dec 17, 2021 | clinicaltrials |
| NCT04955262 | A CD8 Positron Emission Tomography With Computed Tomography (PET/CT) Study Using ⁸⁹Zr Df-IAB22M2C in Patients With Metastatic Melanoma Receiving Bempegaldesleukin (NKTR-214) and Nivolumab | withdrawn | Phase 1 | 0 | Nektar TherapeuticsINDUSTRY | 1 | Jul 8, 2021 | clinicaltrials |
| NCT04060407 | CD24Fc With Ipilimumab and Nivolumab to Decrease irAE (CINDI)(CINDI) | withdrawn | Phase 1 / Phase 2 | 0 | Oncoimmune, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)INDUSTRY | 1 | Jun 1, 2021 | clinicaltrials |
| NCT03773744 | MG1-MAGEA3 With Ad-MAGEA3 and Pembrolizumab in Patients With Previously Treated Metastatic Melanoma or Cutaneous Squamous Cell Carcinoma(Pelican) | withdrawn | Phase 1 | 0 | Turnstone Biologics, Corp.INDUSTRY | 0 | Apr 6, 2021 | clinicaltrials |
| NCT04125719 | PVSRIPO in Combination With Nivolumab in Melanoma(PPD1) | withdrawn | Phase 1 | 0 | Darell BignerOTHER | 1 | Feb 11, 2020 | clinicaltrials |
| NCT03982134 | PDR001 + Panobinostat for Melanoma and NSCLC | withdrawn | Phase 1 | 0 | Muhammad FurqanOTHER | 0 | Oct 4, 2019 | clinicaltrials |
| NCT03111901 | Low-dose Interleukin-2 and Pembrolizumab in Melanoma and Renal Cell Cancer(UVA-AM-002) | withdrawn | Phase 1 / Phase 2 | 0 | William Grosh, MDOTHER | 1 | Jul 12, 2019 | clinicaltrials |
| NCT02300935 | Study of Trametinib and Nab-paclitaxel in Patients With Melanoma | withdrawn | Phase 1 | 0 | SCRI Development Innovations, LLCOTHER | 1 | May 30, 2019 | clinicaltrials |
| NCT02068079 | A Pilot Study of Trientine With Vemurafenib for the Treatment BRAF Mutated Metastatic Melanoma | withdrawn | Phase 1 | 0 | Duke UniversityOTHER | 1 | Jan 30, 2019 | clinicaltrials |
| NCT02447939 | Pharmacokinetics of Repeat Oral Doses of Dabrafenib and the Combination of Dabrafenib and Trametinib in Chinese Subjects With Melanoma | withdrawn | Phase 1 | 0 | GlaxoSmithKlineINDUSTRY | 0 | Sep 14, 2018 | clinicaltrials |
| NCT03297463 | Radiation Therapy With Combination Immunotherapy for Relapsed/Refractory Metastatic Melanoma | withdrawn | Phase 1 / Phase 2 | 0 | Masonic Cancer Center, University of MinnesotaOTHER | 1 | Aug 1, 2018 | clinicaltrials |
| NCT03326258 | Glembatumumab Vedotin, Nivolumab, and Ipilimumab in Treating Patients With Advanced Metastatic Solid Tumors That Cannot Be Removed by Surgery | withdrawn | Phase 1 / Phase 2 | 0 | National Cancer Institute (NCI)NIH | 0 | Jul 18, 2018 | clinicaltrials |
| NCT02839694 | Adjuvant Oral Decitabine and Tetrahydrouridine With or Without Celecoxib in People Undergoing Pulmonary Metastasectomy | withdrawn | Phase 1 | 0 | National Cancer Institute (NCI)NIH | 0 | Jul 5, 2018 | clinicaltrials |
| NCT02915666 | A Clinical Trial of Patients With Melanoma | withdrawn | Phase 1 | 0 | University of Texas Southwestern Medical CenterOTHER | 1 | May 15, 2018 | clinicaltrials |
| NCT03282188 | REO13 Melanoma With of Without GM-CSF | withdrawn | Phase 1 / Phase 2 | 0 | University of LeedsOTHER | 0 | May 4, 2018 | clinicaltrials |
| NCT02812693 | Pembrolizumab and Imatinib in Patients With Locally Advanced/Metastatic Melanoma With c-KIT Mutation/Amplification | withdrawn | Phase 1 / Phase 2 | 0 | Joanne JeterOTHER | 0 | Apr 5, 2018 | clinicaltrials |
| NCT00769990 | Genistein in Treating Patients Undergoing External-Beam Radiation Therapy for Bone Metastases | withdrawn | Phase 1 / Phase 2 | 0 | Masonic Cancer Center, University of MinnesotaOTHER | 0 | Dec 13, 2017 | clinicaltrials |
| NCT02719015 | Dose Escalation and Cohort Expansion of Safety and Tolerability Study of Intratumoral rAd.CD40L (ISF35) in Combination of Systemic Pembrolizumab in Patients With Refractory Metastatic Melanoma | withdrawn | Phase 1 / Phase 2 | 0 | M.D. Anderson Cancer CenterOTHER | 0 | Nov 24, 2017 | clinicaltrials |
| NCT02736123 | Neoadjuvant Combination Biotherapy With Ipilimumab and Nivolumab or Nivolumab Alone | withdrawn | Phase 1 / Phase 2 | 0 | University of PittsburghOTHER | 1 | Sep 20, 2017 | clinicaltrials |
| NCT02489266 | In Vivo Persistence of Adoptively-Transferred TIL Cultured With Akti in People With Metastatic Melanoma | withdrawn | Phase 1 | 0 | National Cancer Institute (NCI)NIH | 0 | Jul 27, 2017 | clinicaltrials |
| NCT02210104 | Adoptive Therapy Using Antigen-Specific CD4 T-Cells | withdrawn | Phase 1 | 0 | M.D. Anderson Cancer CenterOTHER | 0 | Jul 21, 2017 | clinicaltrials |
| NCT01843738 | Radiation Use During Vemurafenib Treatment | withdrawn | Phase 1 | 0 | University of UtahOTHER | 1 | May 24, 2017 | clinicaltrials |
| NCT02661100 | A Trial of CDX-1401 in Combination With Poly-ICLC and Pembrolizumab, in Previously Treated Advanced Solid Tumor Patients | withdrawn | Phase 1 / Phase 2 | 0 | Case Comprehensive Cancer CenterOTHER | 0 | Dec 7, 2016 | clinicaltrials |
| NCT01765556 | A Pharmacokinetics Study to Investigate the Effect of Ketoconazole on Vemurafenib in Patients With BRAFV600 Mutation-Positive Metastatic Melanoma | withdrawn | Phase 1 | 0 | Hoffmann-La RocheINDUSTRY | 0 | Nov 2, 2016 | clinicaltrials |
| NCT02862145 | Pharmacodynamics Study of MRX34, MicroRNA Liposomal Injection in Melanoma Patients With Biopsy Accessible Lesions(MRX34-102) | withdrawn | Phase 1 / Phase 2 | 0 | Mirna Therapeutics, Inc.INDUSTRY | 0 | Sep 27, 2016 | clinicaltrials |
| NCT02065466 | Combo of Abraxane, TMZ, Bevacizumab in Metastatic Melanoma With Brain Metastases | withdrawn | Phase 1 / Phase 2 | 0 | University of ArizonaOTHER | 1 | Apr 21, 2016 | clinicaltrials |
| NCT02452281 | Pilot Study to Evaluate the Effects of a Vaccine (HSPPC-96) Combined With Ipilimumab in Patients With Advanced Melanoma | withdrawn | Phase 1 / Phase 2 | 0 | Rabih SaidOTHER | 1 | Jan 25, 2016 | clinicaltrials |
| NCT02357732 | Study of the Anti-PD-1 Antibody Nivolumab in Combination With Dabrafenib and/or Trametinib | withdrawn | Phase 1 | 0 | University of PittsburghOTHER | 0 | Dec 11, 2015 | clinicaltrials |
| NCT00006126 | Peripheral Stem Cell Transplantation in Treating Patients With Melanoma or Small Cell Lung, Breast, Testicular, or Kidney Cancer That is Metastatic or That Cannot Be Treated With Surgery | withdrawn | Phase 1 | 0 | Northwestern UniversityOTHER | 0 | Nov 13, 2015 | clinicaltrials |
| NCT01764009 | Safety and Efficacy of Intramuscular Electrotransfer of Plasmid AMEP in Patients Suffering From Advanced or Metastatic Melanoma(AIMM) | withdrawn | Phase 1 / Phase 2 | 0 | Valerio TherapeuticsINDUSTRY | 2 | Sep 11, 2015 | clinicaltrials |
| NCT00661336 | A Phase I Trial of Normothermic Isolated Limb Infusion (ILI) With Melphalan Plus Buthionine Sulfoximine (BSO) in Patients With Locally Advanced Malignant Melanoma | withdrawn | Phase 1 | 0 | Duke UniversityOTHER | 1 | Mar 13, 2015 | clinicaltrials |
| NCT01531244 | Isolated Limb Infusion Chemotherapy With Targeted Gene Therapy for Advanced, Unresectable Extremity Melanoma | withdrawn | Phase 1 / Phase 2 | 0 | Washington University School of MedicineOTHER | 0 | Jul 18, 2014 | clinicaltrials |
| NCT01689870 | Study of the Combination of Anti-OX40 and Ipilimumab in Patients With Metastatic Melanoma | withdrawn | Phase 1 / Phase 2 | 0 | Ludwig Institute for Cancer ResearchOTHER | 0 | Apr 1, 2014 | clinicaltrials |
| NCT01340729 | Open-Label Study of TPI 287 for Patients With Metastatic Melanoma | withdrawn | Phase 1 / Phase 2 | 0 | M.D. Anderson Cancer CenterOTHER | 1 | Apr 5, 2013 | clinicaltrials |
| NCT01409187 | IPI-Biotherapy for Patients Previously Treated With Cytotoxic Drugs With Metastatic Melanoma | withdrawn | Phase 1 / Phase 2 | 0 | M.D. Anderson Cancer CenterOTHER | 0 | Jan 26, 2012 | clinicaltrials |
| NCT00803374 | Combination of Anti-CD137 & Ipilimumab in Patients With Melanoma | withdrawn | Phase 1 | 0 | Bristol-Myers SquibbINDUSTRY | 1 | Nov 21, 2011 | clinicaltrials |
Data updated 22 days agoSource updated Jan 2, 2026source: clinicaltrials